Steven Lichtman
Stock Analyst at Oppenheimer
(3.08)
# 1,137
Out of 4,935 analysts
68
Total ratings
42.55%
Success rate
13.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $78.86 | +29.34% | 9 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Perform | $110 → $118 | $103.14 | +14.41% | 3 | Jul 24, 2025 | |
| PODD Insulet | Maintains: Outperform | $312 → $324 | $307.10 | +5.50% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $99.26 | +36.01% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $3.52 | +240.91% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $85.75 | +28.28% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $92.88 | +1.21% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $7.19 | +804.03% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $11.23 | +416.47% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $11.82 | -6.94% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $8.51 | +41.01% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $85.58 | +1.66% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.75 | +367.29% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $377.58 | -23.72% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $84.65 | +24.04% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $27.26 | +450.26% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $70.29 | +20.93% | 3 | Sep 4, 2020 |
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $78.86
Upside: +29.34%
Boston Scientific
Jul 24, 2025
Maintains: Perform
Price Target: $110 → $118
Current: $103.14
Upside: +14.41%
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $307.10
Upside: +5.50%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $99.26
Upside: +36.01%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $3.52
Upside: +240.91%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $85.75
Upside: +28.28%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $92.88
Upside: +1.21%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $7.19
Upside: +804.03%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $11.23
Upside: +416.47%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $11.82
Upside: -6.94%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $8.51
Upside: +41.01%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $85.58
Upside: +1.66%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.75
Upside: +367.29%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $377.58
Upside: -23.72%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $84.65
Upside: +24.04%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $27.26
Upside: +450.26%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $70.29
Upside: +20.93%